Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
Study identifier:1839IL/0126
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy
Medical condition
Non Small Cell Lung Carcinoma
Phase
Phase 3
Healthy volunteers
No
Study drug
Iressa (Gefitinib)
Sex
All
Actual Enrollment
490
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jan 2004
Primary Completion Date: -
Study Completion Date: 01 Aug 2007
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 May 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Lucio Crino
Bologna Italy
